Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY APPRISE: Alirocumab in High CV Risk Hypercholesterolemia
NCT02476006Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2015
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Jun 2015; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02476006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476006.